What Happened?
, -based Kura Oncology Appointed Brian Powl as Chief Commercial Officer
Date of management change: August 14, 2023
, -based Kura Oncology Appointed Brian Powl as Chief Commercial Officer
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials in solid tumor and hematologic indications. Our pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, currently in preclinical development.
Brian Powl is Chief Commercial Officer at Kura Oncology. Previously, Brian held various senior HR leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: McGarry Jan, Greenberg Geoff, Barone Stefany, LaGuardia Dominic, Glancy Todd, Spratlin Monica, Moorehead Bryan, Hector Indira, Hunt Dustin, Cornell Robert, Green Ann
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.